SCHEMBL13329615

SCHEMBL13329615

CSc1nc2c(c(=O)n1C(c1ccccc1)c1ccccc1)CN(C(=O)OC(C)(C)C)CC2

nearest known ligand 0.45

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
PARP1 P09874 1/20 0.40
TNKS2 Q9H2K2 1/20 0.40
PARP2 Q9UGN5 1/20 0.40
PDE10A Q9Y233 1/20 0.40
MAPT P10636 2/20 0.39
P2RX3 P56373 3/20 0.39
F12 P00748 1/20 0.38
MGAT2 Q10469 2/20 0.38
MTHFD2 P13995 1/20 0.38
C5AR1 P21730 1/20 0.37
ESR2 Q92731 1/20 0.37
GRAMD1A Q96CP6 1/20 0.37
PDK4 Q16654 1/20 0.37
MTOR P42345 1/20 0.36
MAPK1 P28482 1/20 0.36
NR1H2 P55055 1/20 0.36
TGM2 P21980 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13250044 0.93 PARP1 (0.46) PARP1TNKS2PARP2MAPTP2RX3
SCHEMBL13250117 0.88 PARP1 (0.42) PARP1TNKS2PARP2MAPTP2RX3
SCHEMBL13328836 0.87 MAPT (0.43) PARP1TNKS2PARP2PDE10AMAPT
SCHEMBL13329375 0.87 PARP1 (0.42) PARP1TNKS2PARP2PDE10AMAPT
SCHEMBL13329616 0.87 MAPT (0.43) PARP1TNKS2PARP2PDE10AMAPT
SCHEMBL13328851 0.87 F12 (0.43) PARP1TNKS2PARP2PDE10AMAPT
SCHEMBL3301786 0.85 MGAT2 (0.49) PARP1TNKS2PARP2PDE10AMAPT
SCHEMBL13250069 0.83 PARP1 (0.43) PARP1TNKS2PARP2P2RX3F12
SCHEMBL13328818 0.83 PRLHR (0.42) MAPT
SCHEMBL13329635 0.82 MEN1 (0.34) PARP1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8318751-B2 Pyrimidinone derivatives and methods of use thereof MERCK SHARP & DOHME CORP. (US) 2012-11-27 US disclosed
US-8318751-B2 Pyrimidinone derivatives and methods of use thereof MERCK SHARP & DOHME CORP. (US) 2012-11-27 US disclosed
US-20100113487-A1 PYRIMIDINONE DERIVATIVES AND METHODS OF USE THEREOF MERCK SHARP & DOHME CORP. 2010-05-06 US disclosed
US-20100113487-A1 PYRIMIDINONE DERIVATIVES AND METHODS OF USE THEREOF MERCK SHARP & DOHME CORP. 2010-05-06 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100113487-A1 PYRIMIDINONE DERIVATIVES AND METHODS OF USE THEREOF GPR119, GPR180, GPR17 PARP1 971/4885TNKS2 1527/4885PARP2 1066/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.